In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

John Davis

Writer

London, U.K
A journalist and editor for more than 30 years, John has a broad interest in pharmaceuticals-related health care policy and breakthroughs in scientific and medical research.  He has degrees in biology and biochemical pharmacology.

Latest From John Davis

Pipeline Watch: Phase III Readouts For Dry Eye, Menopause

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

UCB And Microsoft Expand AI Tie-Up Beyond COVID-19

Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.

Deals Artificial Intelligence

Italfarmaco's Givinostat Encouraging In DMD, But Awaiting 2022 Pivotal Study Results

Italy’s Italfarmaco expects top-line data from its pivotal Phase III study of givinostat in Duchenne muscular dystrophy in the middle of next year, as the HDAC inhibitor continues to accrue data from the extension of its Phase II study.

Rare Diseases Clinical Trials

Pipeline Watch: Phase III Results In AMD, Type 2 Diabetes, Psoriasis

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Sobi Eyes International Expansion With Growing Late-Stage Pipeline

Sobi is extending its reach in international markets including Russia and China and expects its late-stage R&D pipeline to drive growth.

Rare Diseases Research and Development Strategies

Basilea Looks To Progress Cancer Pipeline As It Expands Zevtera Use

Switzerland’s Basilea Pharmaceutica is progressing its lead oncology candidates and a second late-stage US clinical trial of ceftobiprole in difficult-to-treat infections.

Infectious Diseases Research and Development Strategies
See All
UsernamePublicRestriction

Register